ArticleACS pharmacology & translational science2025
Synthesis and Biological Evaluation of Metamorphine: A Morphine-Metamizole Adduct from Patient-Controlled Analgesia Pumps.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioids are among the most effective drugs in managing moderate to severe pain. Herein, we describe a morphine-metamizole adduct with a phenazone moiety added at position C2 of the morphinan backbone. This adduct, coined metamorphine, was first detected as a byproduct of the morphine-metamizole drug interaction in patient-controlled analgesia (PCA) pumps used for management of severe pain. In this study, metamorphine was successfully synthesized using the Mannich condensation. Qualitative high-performance liquid chromatography with ultraviolet detection (HPLC-UV) analysis was employed to confirm the identity of metamorphine, and the yield was then purified using preparative HPLC. Subsequent studies were undertaken to investigate the pharmacological properties of the newly synthesized compound. A radioligand-based binding assay demonstrated that metamorphine binds strongly to the μ-opioid receptor (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.